Already approved in later stage and high-risk cHL, the goal of ongoing Adcetris studies is to “develop curative treatments that improve survival while also reducing toxicity,” Jeremy Abramson, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and principal investigator for the Phase II trial, said in a statement.
Tag Archive for: Seagen
The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.
Data from a new head-to-head study showed BMS’ Opdivo induced better progression-free survival among Hodgkin’s lymphoma patients than Seagen’s Adcetris.
The company struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies as it prepares for a steep fall in COVID-19 sales and generic competition for some top-selling drugs.
The FDA has approved the combination regimen of Merck’s Keytruda (pembrolizumab) and Seagen and Astellas’ Padcev (enfortumab vedotin-ejfv) for the first-line treatment of locally advanced or metastatic urothelial carcinoma, the companies announced Monday.
Pfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatments portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.
Following its failed deal with Merck last year, Seagen has a new suitor. The Seattle-based company is in talks with Pfizer over a potential acquisition, The Wall Street Journal reported Sunday evening, citing people familiar with the matter.
The Washington-based biotech is focusing on upcoming label expansions and its promising pipeline.
With the approval, Tukysa became the first FDA-approved treatment for RAS wild-type, HER2-positive metastatic colon cancer, a cancer with historically poor outcomes.
A review of the latest executive moves in the pharma industry over the past several months.
